



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Earl Ray Tomblin
Governor

Bureau for Medical Services
Pharmacy Services
350 Capitol Street – Room 251
Charleston, West Virginia 25301-3706
Telephone: (304) 558-1700 Fax: (304) 558-1542

Karen L. Bowling
Cabinet Secretary

Pharmaceutical and Therapeutics
Committee
October 26th, 2016

Location: Diamond, Rooms B10 and B11
Time: 9:00 AM – 5:00 PM
Charleston, WV 25301
(304) 558-1700

MINUTES

Committee Members Present:

Robert Stanton, Pharm.D., Chair
Steve Neal, Pharm.D.
Bradley Henry, M.D., Vice Chair
Elizabeth Baldwin, RN, MSN, PNP,
APRN-BC
Kenneth Hilsbos, M.D.
Tom Kines, R.Ph.
Mary Payne, M.D.

Absent:

Hazi Nazha, M.D.
Scott Brown, R.Ph.
Chris Terpening, Pharm.D., PhD.
Adam Breinig, D.O.

Division of Medicaid Staff Present:

Vicki Cunningham, R.Ph.
Brian Thompson, Pharm.D., MS
Bill Hopkins
Doug Sorvig
Gail Goodnight

Contract Staff Present:

Change Healthcare
Brent Breeding, R.Ph.
Lauren Biczak, DO
Jenn Seymour, Project Coordinator

Other Contract / State Staff Present:

Dr. James Becker, BMS Medical Director

I. Call to Order

Bradley Henry, M.D, Vice Chairman, called the meeting to order at 9:10am.

II. Welcome and Introductions

Dr. Henry welcomed all present to the committee meeting. Committee members, BMS staff, and CHC staff introduced themselves. No attendees were present by phone.

III. Administrative Items / Updates

A. Approval of the August 24th, 2016 Minutes

The Committee moved to approve the August Meeting minutes. All were in favor with no objections or revisions.

B. PDL Compliance / Generic Percent Report Updates

Dr. Biczak provided an explanation of the PDL Compliance and Generic Percent reports.

A. Dr. Biczak reviewed the Generic Percent Report; overall generic utilization for Q3 2015 was 86.2%.

B. Dr. Biczak reviewed the PDL Compliance Report; overall compliance for Q3 2015 was 90.2%.

IV. Drug Class Announcements

No drug class announcements were made.

V. Extractions – First Round

CHC recommended that the following classes be extracted:

- Angiotensin Modulators
- Anticonvulsants
- Antipsychotics, Atypical
- Colony Stimulating Factors
- COPD Agent
- Cytokine & Cam Antagonists
- Hepatitis C Treatments
- Multiple Sclerosis Agents
- Ophthalmics, Anti-Inflammatories-Immunomodulators
- Otic Antibiotics

- Stimulants & Related Agents

Additional extractions presented by Committee members:

Tom Kines: Lipotropics, Statins

Robert Stanton: Anticoagulants, Hypoglycemics, Incretin Mimetics/Enhancers and Hypoglycemics, Sodium Glucose Cotransporter-2 Inhibitors.

Beth Baldwin: Bronchodilators, Beta Agonists.

VI. Extractions – Second Round

No further objections or additions were made to the individual extractions as presented in the agenda or the second round of Committee extractions. Vicki Cunningham summarized the second round of extractions.

VII. Public Comments

Vicki Cunningham called the first speaker at 9:18am. She described the 3-minute limit per speaker, per drug.

Brian Howell representing Perdue spoke on behalf of Hyslinga.

Gregg Morrow representing Sanofi spoke on behalf of Aubagio.

Gina McKnight-Smith representing Abbvie spoke on behalf of Zinbryta.

Sharad Rastogi representing Shire spoke on behalf of Xiidra.

Kelly Broderick representing Sonovion spoke on behalf of Aptiom, Latuda and Neupro.

Jason Moyer representing UCB spoke on behalf of Briviact, Vimpat and Neupro.

Bobby Arelli representing AstraZeneca spoke on behalf of Brilinta and Movantik.

Cynthia Smith representing Abbvie spoke on behalf of Viekira Pak and Viekira XR.

Ahmad Nessar representing Amgen spoke on behalf of Enbrel and Repatha.

Bruce Wallace representing Silvergate spoke on behalf of Qbrexelis.

Amber Root representing Actelion spoke on behalf of Opsumit and Upravi.

Jon Vlasnik representing Boehringer Ingleheim spoke on behalf of Jardiance.

Chad Patel representing BristolMyersSquib spoke on behalf of Daklinza, Eliquis and Orenzia.

Steve Babineaux representing Eli Lilly spoke on behalf of Taltz.

Mark Bernarducci representing Mylan spoke on behalf of Epipen.

Heidi Benden representing Tris Pharma spoke on behalf of Dyanavel XR.

Juan Avila representing UCB spoke on behalf of Cimzia.

Mark Veerman representing Jansen spoke on behalf of Invokana and Invokamet.

Jennifer Bennett representing Biogen spoke on behalf of Tecfidera.

William Mullen representing Indivior yielded his time back to the committee.

Bhahsha Desai representing United Therapeutics spoke on behalf of Orenitram.

Ndidi Yaucher representing Novartis yielded her time back to the committee.

VIII. Executive Session

The Committee adjourned for Executive Session at 10:25am.

IX. Lunch Break

The Committee's lunch break was taken during the Executive Session.

X. Third Round Extractions

Dr. Henry reconvened the meeting at 1:26pm.

Additional extractions presented by Committee members:

Beth Baldwin: Epinephrine

XI. Motion for All Non-Extracted Categories to Approved as Proposed

CHC recommended that the following list be approved without extraction.

- Acne Agents, Topical
- Alzheimer's Agents
- Analgesics, Narcotics- Long Acting (Non-Parenteral)
- Analgesics, Narcotics- Short Acting (Non-Parenteral)
- Androgenic Agents
- Anesthetics, Topical
- Antianginal & Anti-Ischemic
- Antibiotics (GI)
- Antibiotics, Inhaled
- Antibiotics, Topical
- Antibiotics, Vaginal
- Antidepressant-Other
- Antidepressants- SSRIs
- Antiemetics
- Antifungals, Oral
- Antifungals, Topical
- Antihypertensives, Sympatholytics
- Antihyperuricemics
- Antimigraine Agents, Other
- Antimigraine Agents, Triptans
- Antiparasitics, Topical
- Antipsoriatics, Topical
- Antiretrovirals
- Antivirals, Oral
- Antivirals, Topical

- Beta Blockers
- Bladder Relaxant Preparations
- Bone Resorption Suppression & Related Agents
- BPH Treatments
- Bronchodilators, Beta Agonists
- Calcium Channel Blockers
- Cephalosporins & Related Antibiotics
- Epinephrine, Self-Injected
- Erythropoiesis Stimulating Proteins
- Fluoroquinolones (Oral)
- Glucocorticoids, Inhaled
- Growth Hormones
- H. Pylori Treatment
- Hepatitis B Treatments
- Hyperparathyroid Agents
- Hypoglycemics, Biguanides
- Hypoglycemics, Bile Acid Sequestrants
- Hypoglycemics, Incretin Mimetics/Enhancers
- Hypoglycemics, Insulins & Related Agents
- Hypoglycemics, Meglitinides
- Hypoglycemics, Sodium Glucose Cotransporter-2 Inhibitors
- Hypoglycemics, TZDs
- Immune Globulins, IV
- Immune Globulins, Other
- Immunomodulators, Atopic Dermatitis
- Immunomodulators, Genital Warts & Actinic Keratosis Agents
- Immunosuppressive, Oral
- Intranasal Rhinitis Agents
- Irritable Bowel Syndrome/Short Bowel Syndrome/Selected GI Agents
- Laxatives and Cathartics
- Leukotriene Modifiers
- Lipotropics, Other (Non-Statins)
- Lipotropics, Statins
- Macrolide/Ketolides
- Neuropathic Pain
- NSAIDs
- Ophthalmic Antibiotics
- Ophthalmic Antibiotics/Steroid Combinations
- Ophthalmics for Allergic Conjunctivitis
- Ophthalmics, Anti-Inflammatories
- Ophthalmics, Glaucoma Agents
- Opiate Dependence Treatments
- PAH Agents – Endothelin Receptor Antagonists
- PAH Agents – Guanylate Cyclase Stimulator
- PAH Agents – PDE5s
- PAH Agents - Prostacyclins

- Pancreatic Enzymes
- Phosphate Binders
- Platelet Aggregation Inhibitors
- Progestins for Cachexia
- Proton Pump Inhibitors
- Sedative Hypnotics
- Skeletal Muscle Relaxants
- Steroids, Topical
- Tetracyclines
- Ulcerative Colitis Agents
- Vasodilators, Coronary

A motion was made to accept all non-extracted categories as presented by CHC. All members were in favor and the motion was approved.

XII. Extracted Therapeutic Category Reviews/Committee Recommendations

A. Angiotensin Modulator

CHC recommended that the following list be approved. Dr. Henry moved to accept the recommendation with the amendment to move the following drugs from Preferred to Non-Preferred status: AZOR, TRIBENZOR, MICARDIS, MICARDIS HCT, BENICAR and BENICAR HCT. Dr. Neal seconded. Votes were taken, and the motion was adopted. The approved category is below.

ANGIOTENSIN MODULATORS^{AP}	
	ACE INHIBITORS
benazepril	ACCUPRIL (quinapril)
captopril	ACEON (perindopril)
enalapril	ALTACE (ramipril)
fosinopril	EPANED (enalapril)*
lisinopril	LOTENSIN (benazepril)
quinapril	MAVIK (trandolapril)
ramipril	moexipril
	perindopril
	PRINIVIL (lisinopril)
	QBRELIS SOLUTION (lisinopril)
	trandolapril
	UNIVASC (moexipril)
	VASOTEC (enalapril)
	ZESTRIL (lisinopril)
	ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)
irbesartan	ATACAND (candesartan)
losartan	AVAPRO (irbesartan)
valsartan	BENICAR (olmesartan)
	candesartan

	COZAAR (losartan) DIOVAN (valsartan) EDARBI (azilsartan) eprosartan MICARDIS (telmisartan) telmisartan TEVETEN (eprosartan)
ARB COMBINATIONS	
ENTRESTO (valsartan/sucubitril)* irbesartan/HCTZ losartan/HCTZ valsartan/amlodipine valsartan/HCTZ	ATACAND-HCT (candesartan/HCTZ) AVALIDE (irbesartan/HCTZ) AZOR (olmesartan/amlodipine) BENICAR-HCT (olmesartan/HCTZ) BYVALSON (nebivolol/valsartan) candesartan/HCTZ DIOVAN-HCT (valsartan/HCTZ) EDARBYCLOR (azilsartan/chlorthalidone) EXFORGE (valsartan/amlodipine) EXFORGE HCT (valsartan/amlodipine/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ) telmisartan/amlodipine telmisartan HCTZ TEVETEN-HCT (eprosartan/HCTZ) TRIBENZOR (olmesartan/amlodipine/HCTZ) TWYNSTA (telmisartan/amlodipine) valsartan/amlodipine/HCTZ

B. Anticonvulsants

CHC recommended that the following list be approved. Elizabeth Baldwin moved to accept the recommendation. Dr. Henry seconded. A robust clinical discussion followed. Votes were taken, and the motion was adopted. The approved category is below.

ANTICONVULSANTS	
	ADJUVANTS
carbamazepine carbamazepine ER carbamazepine XR DEPAKOTE SPRINKLE (divalproex) divalproex divalproex ER EPITOL (carbamazepine) GABITRIL (tiagabine) lamotrigine levetiracetam IR levetiracetam ER oxcarbazepine suspension and tablets topiramate IR topiramate ER* valproic acid VIMPAT(lacosamide) ^{AP**} zonisamide	APTIOM (eslicarbazepine) BANZEL(rufinamide) BRIVIACT (brivaracetam) CARBATROL (carbamazepine) DEPAKENE (valproic acid) DEPAKOTE (divalproex) DEPAKOTE ER (divalproex) divalproex sprinkle EQUETRO (carbamazepine) FANATREX SUSPENSION (gabapentin) felbamate FELBATOL (felbamate) ^{***} FYCOMPA (perampanel) KEPPRA (levetiracetam) KEPPRA XR (levetiracetam) LAMICTAL (lamotrigine) LAMICTAL CHEWABLE (lamotrigine) LAMICTAL ODT (lamotrigine) LAMICTAL XR (lamotrigine) lamotrigine dose pack

lamotrigine ER ONFI (clobazam) **** ONFI SUSPENSION (clobazam) **** OXTELLAR XR (oxcarbazepine) POTIGA (ezogabine) QUDEXY XR (topiramate ER) SABRIL (vigabatrin) SPRITAM (levetiracetam) STAVZOR (valproic acid) TEGRETOL (carbamazepine) TEGRETOL XR (carbamazepine) tiagabine TOPAMAX (topiramate) TRILEPTAL SUSPENSION and TABLETS (oxcarbazepine) TROKENDI XR (topiramate) ZONEGRAN (zonisamide)

C. Antipsychotics, Atypical

CHC recommended that the following list be approved. Elizabeth Baldwin moved to accept the recommendation. Dr. Neal seconded. Votes were taken, and the motion was adopted. The approved category is below.

ANTIPSYCHOTICS, ATYPICAL	
SINGLE INGREDIENT	
ABILIFY MAINTENA (aripiprazole)* CL	ABILIFY TABLETS (aripiprazole)
ABILIFY DISCMELT & ORAL SOLUTION (aripiprazole)	ADASUVE (loxapine)
aripiprazole tablets	aripiprazole discmelt & oral solution
clozapine	ARISTADA (aripiprazole)*****
INVEGA SUSTENNA (paliperidone)* CL	clozapine ODT
INVEGA TRINZA (paliperidone)** CL	CLOZARIL (clozapine)
LATUDA (lurasidone)*** AP	FANAPT (iloperidone)
olanzapine	FAZACLO (clozapine)
olanzapine ODT	GEODON (ziprasidone)
quetiapine**** AP for the 25 mg Tablet Only	GEODON IM (ziprasidone)
RISPERDAL CONSTA (risperidone) * CL	INVEGA (paliperidone)
risperidone	NUPLAZID (pimavanserin)
ziprasidone	olanzapine IM*
	paliperidone ER
	REXULTI (brexpiprazole)
	RISPERDAL (risperidone)
	SAPHRIS (asenapine)
	SEROQUEL (quetiapine)
	SEROQUEL XR (quetiapine)
	VERSACLOZ (clozapine)
	VRAYLAR (cariprazine)
	VRAYLAR DOSE PAK (cariprazine)
	ZYPREXA (olanzapine)
	ZYPREXA IM (olanzapine)*
	ZYPREXA RELPREVV (olanzapine)

D. Colony Stimulating Factors

CHC recommended that the following list be approved. Elizabeth Baldwin moved to accept the recommendation. Dr. Henry seconded. Votes were taken, and the motion was adopted. The approved category is below.

COLONY STIMULATING FACTORS

GRANIX (tbo-filgrastim)
LEUKINE (sargramostim)
NEUPOGEN (filgrastim)

NEULASTA (pegfilgrastim)
ZARXIO (filgrastim)

E. COPD Agents

CHC recommended that the following list be approved with the exception on moving Atrovent from Preferred to Non-Preferred status. Dr. Henry moved to accept the recommendation. Elizabeth Baldwin seconded. Votes were taken, and the motion was adopted. The approved category is below.

COPD AGENTS

ANTICHOLINERGIC^{AP}

ipratropium
SPIRIVA (tiotropium)

ATROVENT HFA (ipratropium)
INCRUSE ELLIPTA (umeclidinium)
SPIRIVA RESPIMAT (tiotropium)
TUDORZA (aclidinium)

ANTICHOLINERGIC-BETA AGONIST COMBINATIONS^{AP}

albuterol/ipratropium
COMBIVENT RESPIMAT (albuterol/ipratropium)

ANORO ELLIPTA (umeclidinium/vilanterol)*
BEVESPI (glycopyrrolate/formoterol)
DUONEB (albuterol/ipratropium)
STIOLTO RESPIMAT (tiotropium/olodaterol)*

F. Cytokine & Cam Antagonists

CHC recommended that the following list be approved. Dr. Henry moved to accept the recommendation. Elizabeth Baldwin seconded. Votes were taken, and the motion was adopted. The approved category is below.

CYTOKINE & CAM ANTAGONISTS^{CL}

OTHERS

COSENTYX (secukinumab)*

ACTEMRA syringe (tocilizumab)
KINERET (anakinra)
ORENCIA syringe (abatacept)
OTEZLA (apremilast)
STELARA syringe (ustekinumab)
TALTZ (ixekizumab)
XELJANZ (tofacitinib)
XELJANZ XR (tofacitinib)

G. Epinephrine, Self-Injected

CHC recommended that the following list be approved. Elizabeth Baldwin moved to accept the recommendation. Dr. Henry seconded. Votes were taken, and the motion was adopted. The approved category is below.

EPINEPHRINE, SELF-INJECTED

epinephrine	ADRENALICK (epinephrine) EPIPEN (epinephrine) EPIPEN JR (epinephrine)
-------------	---

H. Fluoroquinolones (Oral)

CHC recommended that the following list be approved. Dr. Stanton moved to accept the recommendation. Dr. Neal seconded. Votes were taken, and the motion was adopted. The committee then recommended that the DUR Board make the final vote for this therapeutic class. Dr. Hilsbos moved to accept the recommendation. Elizabeth Baldwin seconded. Votes were taken and the motion was adopted. The approved category is below.

FLUOROQUINOLONES (Oral)^{AP}

CIPRO SUSPENSION (ciprofloxacin) ciprofloxacin levofloxacin tablet	AVELOX (moxifloxacin) CIPRO TABLETS (ciprofloxacin) CIPRO XR (ciprofloxacin) ciprofloxacin ER ciprofloxacin suspension FACTIVE (gemifloxacin) LEVAQUIN (levofloxacin) levofloxacin solution moxifloxacin NOROXIN (norfloxacin) ofloxacin
--	--

I. Glucocorticoids, Inhaled

CHC recommended that the following list be approved. Elizabeth Baldwin moved to accept the recommendation. Dr. Hilsbos seconded. Votes were taken, and the motion was adopted. The approved category is below.

GLUCOCORTICIDS, INHALED^{AP}

GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS	
ADVAIR DISKUS (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol) BREQ ELLIPTA (fluticasone/vilanterol) DULERA (mometasone/formoterol) SYMBICORT (budesonide/formoterol)	

J. Hepatitis C Treatments

CHC recommended that the following list be approved. Elizabeth Baldwin moved to accept the recommendation. Dr. Henry seconded. A robust clinical discussion followed. Votes were taken, and the motion was adopted. The approved category is below.

HEPATITIS C TREATMENTS^{CL}

<p>EPCLUSA (sofosbuvir/velpatasvir) HARVONI (ledipasvir/sofosbuvir)* PEGASYS (pegylated interferon) PEG-INTRON (pegylated interferon) ribavirin SOVALDI (sofosbuvir)* TECHNIVIE (ombitasvir/paritaprevir/ritonavir)* VIEKIRA PAK (dasabuvir/ombitasvir/ paritaprevir/ritonavir)* VIEKIRA XR (dasabuvir/ombitasvir/ paritaprevir/ritonavir)* ZEPATIER (elbasvir/grazoprevir)</p>	<p>COPEGUS (ribavirin) DAKLINZA (daclatasvir)* MODERIBA 400 mg, 600 mg MODERIBA DOSE PACK OLYSIO (simeprevir)* REBETOL (ribavirin) RIBASPHERE RIBAPAK (ribavirin) RIBASPHERE 400 mg, 600 mg (ribavirin)</p>
--	--

K. Hypoglycemics, Incretin Mimetics/Enhancers

CHC recommended that the following list be approved. Dr. Henry moved to accept the recommendation. Elizabeth Baldwin seconded. Votes were taken, and the motion was adopted. The approved category is below.

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	
ORAL	
<p>JANUMET (sitagliptin/metformin) ^{AP} JANUVIA (sitagliptin)^{AP} JENTADUETO (linagliptin/metformin) ^{AP} TRADJENTA (linagliptin) ^{AP}</p>	<p>JANUMET XR (sitagliptin/metformin) JENTADUETO XR (linagliptin/metformin) KAZANO (alogliptin/metformin) KOMBIGLYZE XR (saxagliptin/metformin) NESINA (alogliptin) ONGLYZA (saxagliptin) OSENI (alogliptin/pioglitazone)</p>

L. Hypoglycemics, SGLT2 Inhibitors

Dr. Stanton had asked for this class to be extracted for additional discussion. CHC recommended no changes. Dr. Henry moved to accept the recommendation. Beth Baldwin seconded. Votes were taken, and the motion was adopted. The approved category is below.

HYPOGLYCEMICS, SGLT2 INHIBITORS	
SGLT2 INHIBITORS	
	<p>FARXIGA (dapagliflozin) INVOKANA (canagliflozin) JARDIANCE (empagliflozin)</p>
SGLT2 COMBINATIONS	
	<p>GLYXAMBI (empagliflozin/linagliptin) INVOKAMET (canagliflozin/metformin) SYNJARDY (empagliflozin/metformin) XIGDUO XR (dapagliflozin/metformin)</p>

M. Lipotropics, Other (Non-statins)

CHC recommended that the following list be approved. Dr. Kines moved to accept the recommendation. Dr. Henry seconded. Votes were taken, and the motion was adopted. The approved category is below.

LIPOTROPICS, OTHER (Non-statins)

FIBRIC ACID DERIVATIVES ^{AP}	
fenofibrate 40 mg	ANTARA (fenofibrate)
fenofibrate 54, 150 and 160 mg	FENOGLIDE (fenofibrate)
fenofibrate micronized 67mg, 134mg & 200mg	FIBRICOR (fenofibric acid)
fenofibrate nanocrystallized 48 mg, 145 mg	fenofibrate 43, 50, 120 and 130 mg
gemfibrozil	fenofibric acid
	LIPOFEN (fenofibrate)
	LOFIBRA (fenofibrate)
	LOPID (gemfibrozil)
	TRICOR (fenofibrate nanocrystallized)
	TRIGLIDE (fenofibrate)
	TRILIPIX (fenofibric acid)

N. Multiple Sclerosis Agents

CHC recommended that the following list be approved. Dr. Henry moved to accept the recommendation. Elizabeth Baldwin seconded. Votes were taken, and the motion was adopted. The approved category is below.

MULTIPLE SCLEROSIS AGENTS

NON-INTERFERONS	
COPAXONE 20 mg (glatiramer) ^{AP}	AMPYRA (dalfampridine) ^{CL**}
GILENYA (fingolimod) ^{AP*}	AUBAGIO (teriflunomide) ^{CL***}
	COPAXONE 40 mg (glatiramer) ^{CL****}
	GLATOPA (glatiramer)
	TECFIDERA (dimethyl fumarate) ^{CL*****}
	ZINBRYTA (daclizumab)

O. Ophthalmics, Anti-Inflammatories-Immunomodulators

CHC recommended that the following list be approved. Dr. Henry moved to accept the recommendation. Elizabeth Baldwin seconded. Votes were taken, and the motion was adopted. The approved category is below.

OPHTHALMICS, ANTI-INFLAMMATORIES- IMMUNOMODULATORS

	RESTASIS (cyclosporine)
	XIIDRA (lifitegrast)

P. Ophthalmic, Antibiotic

CHC recommended that the following list be approved. Dr. Henry moved to accept the recommendation. Elizabeth Baldwin seconded. Votes were taken, and the motion was adopted. The approved category is below.

OPHTHALMIC, ANTIBIOTIC	
	RESTASIS (cyclosporine) XIIDRA (lifitegrast)

Q. Otic Antibiotics

CHC recommended that the following list be approved. Dr. Henry moved to accept the recommendation. Elizabeth Baldwin seconded. Votes were taken, and the motion was adopted. The approved category is below.

OTIC ANTIBIOTICS ^{AP}	
CIPRO HC (ciprofloxacin/hydrocortisone) CIPRODEX (ciprofloxacin/dexamethasone) ciprofloxacin COLY-MYCIN S (colistin/hydrocortisone/ neomycin/thonzonium bromide) neomycin/polymyxin/HC solution/suspension	CORTISPORIN-TC (colistin/hydrocortisone/ neomycin) ofloxacin OTOVEL (ciprofloxacin/fluocinolone)

R. Stimulants & Related Agents

CHC recommended that the following list be approved. Elizabeth Baldwin moved to accept the recommendation. Dr. Hilsbos seconded. A robust clinical discussion followed. Votes were taken, and the motion was adopted. The approved category is below.

STIMULANTS AND RELATED AGENTS	
AMPHETAMINES	
ADZENYS XR ODT (dextroamphetamine/amphetamine) amphetamine salt combination IR dextroamphetamine ER dextroamphetamine IR PROCENTRA solution (dextroamphetamine) VYVANSE (lisdexamfetamine)	ADDERALL (amphetamine salt combination) ADDERALL XR* (amphetamine salt combination) amphetamine salt combination ER DESOXYN (methamphetamine) DEXEDRINE ER (dextroamphetamine) DEXEDRINE IR (dextroamphetamine) dextroamphetamine solution DYANAVEL XR (dextroamphetamine/amphetamine) EVEKEO (amphetamine) methamphetamine ZENZEDI (dextroamphetamine)
NON-AMPHETAMINE	

clonidine IR DAYTRANA (methylphenidate) dexmethylphenidate IR FOCALIN XR (dexmethylphenidate) guanfacine ER guanfacine IR METADATE CD (methylphenidate) METHYLIN SOLUTION (methylphenidate) methylphenidate IR QUILLICHEW ER (methylphenidate) QUILLIVANT XR (methylphenidate) STRATTERA (atomoxetine)*	APTENSIO XR (methylphenidate) armodafinil clonidine ER CONCERTA (methylphenidate) dexmethylphenidate XR FOCALIN IR (dexmethylphenidate) INTUNIV (guanfacine extended-release) KAPVAY (clonidine extended-release)** METHYLIN CHEWABLE TABLETS (methylphenidate) methylphenidate chewable tablets, solution methylphenidate CD methylphenidate ER (generic CONCERTA) methylphenidate ER methylphenidate LA modafinil*** NUVIGIL (armodafinil) *** PROVIGIL (modafinil) *** RITALIN (methylphenidate) RITALIN LA (methylphenidate)
--	--

XIII. Next Meeting

The next P&T Committee Meeting is scheduled for January 25th, 2017.

XIV. Other Business

Dr. Stanton announced that Elizabeth Baldwin will be leaving the Committee, Dr. Bradley Henry will be taking over as Chair and Tom Kines will be moving into the Vice Chair position.

Dr. Henry motioned that the DUR Board to review the new Black Box warning for opiate containing products regarding concurrent use with benzodiazepines. . Dr. Payne seconded. Votes were taken and the motion was accepted.

XV. Adjournment

The Committee adjourned the meeting at 1:58pm